skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

ZolpiMistTM: a new formulation of zolpidem tartrate for the short-term treatment of insomnia in the US

Review

(1356) Views  (1106) Full article downloads

Authors: David N Neubauer

Published Date May 2010 Volume 2010:2 Pages 79 - 84
DOI: http://dx.doi.org/10.2147/NSS.S6431

David N Neubauer

Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA

Abstract: ZolpiMist™ is an oral spray formulation of the hypnotic compound zolpidem that was approved by the US Food and Drug Administration in 2008 with an indication for the shortterm treatment of insomnia characterized by difficulty with sleep initiation. It was developed by NovaDel Pharma, Inc. using their patented NovaMist™ spray technology. The recommended doses are 10 mg for adults and 5 mg for elderly and debilitated patients to be taken once daily immediately before bedtime. Each metered spray contains 5 mg of zolpidem. ZolpiMist was approved through the 505(b)(2) pathway, which allowed reference to pre-existing efficacy and safety data for the equivalent doses of zolpidem immediate-release tablets. Bioequivalence and pharmacokinetic characteristics were demonstrated in clinical studies with healthy adult and elderly subjects. ZolpiMist is being investigated for the possible indication of use during middleof-the-night awakenings when the patient has at least 4 hours available to remain in bed.

Keywords: ZolpiMist, zolpidem, oral spray formulation, hypnotic, insomnia






 

Other articles by Dr David Neubauer



Readers of this article also read:

Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Exacerbation rate, health status and mortality in COPD – a review of potential interventions
Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures
New approaches in the treatment of short term and middle of the night insomnia: emerging evidence for a role for sublingual zolpidem tablets
The association between insomnia and cardiovascular diseases
Management of insomnia: update and new approaches
Jet lag syndrome: circadian organization, pathophysiology, and management strategies
Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio